H&R Block reported fiscal 2027 first quarter results with revenue increasing 10% to $224.3 million, driven by growth in international and small business services. The company reaffirmed its full-year fiscal 2027 outlook and returned capital to shareholders through $100 million in share repurchases and a quarterly dividend declaration of $0.46 per share.
“We are pleased with our start to fiscal 2027, including revenue growth of more than 10%. At the same time, we continue advancing strategic initiatives designed to enhance the client experience and support future growth. Our focus remains on executing our strategy and positioning H&R Block for long-term success.”
Curtis Campbell, president and chief executive officer
“Our financial position remains strong, and we continue to execute our disciplined capital allocation priorities. During the first quarter, we invested in the business to support future growth while returning capital to shareholders through dividends and share repurchases. We remain confident in the assumptions underlying our fiscal 2027 outlook and are reaffirming our guidance.”
CEVA INC reported total revenues of $85.1 million for the nine months ended September 30, 2026, a 9% increase compared to the same period in 2025. Despite the revenue growth, the company recorded a net loss of $9.7 million for the period, driven by higher operating expenses in research and development and general and administrative functions.
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.
Term
Q3 2026
“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”
Andrew Dudum, co-founder and CEO
“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”
Life360 reported total revenue of $174.1 million for the quarter ended September 30, 2026, representing significant growth from $124.5 million in the prior year period, driven largely by subscription and advertising revenue. The company maintained a strong balance sheet with $333.1 million in cash and cash equivalents and showed a reduction in its accumulated deficit to $108.5 million.
Clearway Energy reported Q3 2026 net income of $123 million and Adjusted EBITDA of $435 million, driven by contributions from growth investments. The company reaffirmed its 2026 CAFD guidance and initiated 2027 guidance, while highlighting an accelerating growth roadmap with its sponsor-developed pipeline reaching approximately 16 GW.
Term
Q3 2026
“Since last quarter, we have committed to two additional drop-downs from Clearway Energy Group LLC (“Clearway Group”), secured further revenue contracting for our Flexible Generation fleet at long contract tenors, and increased our committed and identified drop-down opportunities (which have increased by over 100% since the beginning of the year), enabling us to reiterate a pathway to the top end or better of our 2030 CAFD per share target.”
Craig Cornelius, the Company’s President and Chief Executive Officer
“Following our annual strategic planning process, we are also pleased to announce our initial 2031 financial target range of $3.20 to $3.40 of CAFD per share, representing a compound annual growth rate of 7–8% from our 2025 baseline.”
Craig Cornelius, the Company’s President and Chief Executive Officer
Amplify Energy reported Q3 2026 financial results featuring a 9% sequential increase in total production to 7.4 MBopd, driven by development activity at the Beta field. The company reported a net loss of $18.9 million primarily due to commodity derivative changes, while achieving Adjusted EBITDA of $10.8 million and securing enhanced royalty relief at Beta.
Term
Q3 2026
“Our third-quarter results demonstrate tangible progress in unlocking the value of Amplify’s asset base, with growing production across both assets and significantly lower costs at Bairoil. During the third quarter, strong performance from the recently drilled C29 and C16 wells, together with End of Life royalty relief, meaningfully increased net production, revenue and cash flow at Beta.”
Network-1 Technologies reported a net loss of $2.33 million for Q3 2026 on zero revenue, compared to a $0.56 million loss in the prior year period. The increased loss was primarily driven by higher litigation-related professional fees and unrealized losses on marketable securities. The company continues to pursue patent litigation against Samsung with a trial date scheduled for June 2027.
Insight Digital Partners II reported net income of $1.45 million for the quarter ended September 30, 2026, primarily driven by $1.61 million in interest earned on investments held in the Trust Account. As a blank check company, it has not yet generated operating revenue and is currently focused on identifying a target for a business combination.
Hyperfine, Inc. reported total sales of $13.77 million for the nine months ended September 30, 2026, a significant increase from $8.27 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $23.90 million for the period, though this was an improvement over the $29.66 million net loss reported in the same period of 2025.
Kaltura Inc. reported its financial results for the quarter ended September 30, 2026, maintaining its status as an accelerated filer and emerging growth company. The company continues to navigate a history of losses and geopolitical risks related to its operations in Israel, while focusing on the integration of AI technologies and subscription-based revenue growth.
Standard Premium Finance Holdings reported total revenues of $10.36 million for the nine months ended September 30, 2026, a 12.3% increase over the prior year. Net income attributable to common stockholders rose to $1.10 million compared to $0.78 million in 2025, driven by higher finance charges despite increased interest expenses and credit loss provisions.
Independent Bank Corp reported net income of $89.7 million for the third quarter of 2026, a significant increase from $34.3 million in the prior year period, driven by higher net interest income and lower provisions for credit losses. Total assets remained stable at $25.0 billion, while the company experienced a decrease in total stockholders' equity due to share repurchases and accumulated other comprehensive losses.
For the nine months ended September 30, 2026, Uniti Group reported total revenues of $2.75 billion, a significant increase from $1.32 billion in the prior year period, though it recorded a net loss of $470.7 million compared to a net income of $1.61 billion in 2025. The company's balance sheet shows a total asset base of $13.5 billion and a shift to a total shareholders' deficit of $79.5 million as of September 30, 2026.
Take-Two Interactive reported fiscal second quarter 2027 results with GAAP net revenue of $1.50 billion and a net loss of $54.0 million. The company reiterated its full-year Net Bookings guidance of $8.0 to $8.2 billion, driven by the upcoming launch of Grand Theft Auto VI.
Term
Q2 2027
“The launch of Grand Theft Auto VI is ten days away and, with pre-orders continuing to reach unprecedented levels, we expect to deliver an historic year for our company. We are reiterating our outlook for Fiscal 2027 Net Bookings of $8 to $8.2 billion, and are confident in our ability to build on this incredible year as we release new hits, explore emerging business opportunities, expand our geographic footprint, and pursue accretive M&A – all of which will set us on a path to unlock greater earnings power and long-term shareholder value.”
Strauss Zelnick, Chairman and CEO of Take-Two Interactive
GeneDx reported Q3 2026 revenue of $123.1 million, driven by 25% year-over-year growth in exome and genome test volume. The company achieved adjusted net income of $8.6 million and expanded its adjusted gross margin to 72%. Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
Term
Q3 2026
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
Myomo reported record third-quarter revenue of $12.3 million, a 22% year-over-year increase driven by a shift toward recurring patient sources. The company achieved breakeven Adjusted EBITDA and narrowed its full-year 2026 revenue guidance to the upper end of its previous range.
Term
Q3 2026
“The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and sequentially lower cash burn.”
Paul R. Gudonis, Chairman and Chief Executive Officer
Groupon, Inc. filed its 10-Q for the period ending September 30, 2026, highlighting a transition toward an AI-native business model and the implementation of a May 2026 restructuring plan. The company continues to manage significant debt obligations, including the 2026, 2027, and 2030 convertible senior notes, while navigating global economic uncertainty and inflationary pressures.
Immunome Inc. reported a net loss of $212.4 million for 2025, an improvement from $293.0 million in 2024, primarily due to a significant decrease in in-process research and development expenses. The company significantly strengthened its liquidity position, ending 2025 with $653.5 million in cash and cash equivalents following two major public offerings that raised over $594 million in net proceeds.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing ficerafusp alfa, reporting 66,387,197 shares of common stock outstanding as of November 3, 2026. The company continues to incur significant financial losses and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Crescent Capital BDC reported Q3 2026 financial results with net investment income of $0.37 per share and a net asset value of $17.72 per share. The company also declared a $0.34 per share quarterly dividend and authorized a new $50 million share repurchase program.
Greystone Housing Impact Investors LP reported Q3 2026 net income of $3.2 million and Cash Available for Distribution (CAD) of $3.8 million. The Partnership is executing a strategic shift to reduce capital allocation in market-rate multifamily joint ventures in favor of tax-exempt mortgage revenue bond investments to stabilize long-term earnings.
Term
Q3 2026
“The Partnership continues to work with the managing members of our market rate multifamily properties to position our remaining investments in this segment for sale. We are working with third-party brokers and property management firms to plan potential exit timelines based on current property level leasing activity and operating results. We are also working with our internal origination team and the broader Greystone affordable platform to identify traditional mortgage revenue bond investment opportunities where we can redeploy capital.”
Kenneth C. Rogozinski, Chief Executive Officer of the Partnership
Paradium.AI reported Q3 2026 revenue of $20.5 million, a 31.2% decline year-over-year driven by lower referral traffic from platforms like Google Discover. The company posted a net loss of $3.8 million compared to net income in the prior year, as it continues a strategic shift toward AI-powered monetization and content tools to reduce dependence on external traffic sources.
Term
Q3 2026
“We continue to see tremendous opportunity in the age of AI, and we’re all in. While retaining referral traffic remains part of our focus, our real momentum is powered by tools like Cutter Studios and InfoSentience, which are already increasing output and efficiency.”
Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.
Term
Q3 2026
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”
StepStone Group Inc. reported total assets of $9.26 billion as of September 30, 2026, a significant increase from $6.76 billion in March 2026, primarily driven by growth in investments and assets of consolidated funds. The company remains a large accelerated filer with 82,475,390 shares of Class A common stock outstanding as of November 3, 2026.
Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.
Zymeworks Inc. reported a significant increase in total revenue to $256.5 million for the third quarter of 2026, primarily driven by $250.0 million in license and milestone revenue. The company achieved a net income of $173.7 million for the quarter, a substantial improvement from the $19.6 million net loss in the prior year period, despite an increase in operating expenses to $78.9 million.
Ethan Allen reported fiscal 2027 first quarter results with consolidated net sales of $129.6 million, down from $147.0 million in the prior year. The company's margins were pressured by lower sales volumes and new Section 301 tariffs, though it maintained a strong cash position of $92.2 million with no debt. Despite a soft housing market, retail written orders showed sequential momentum, rising 13.2% compared to the previous quarter.
The Trade Desk reported Q3 2026 revenue of $736 million and GAAP net income of $38 million, while also announcing a $731 million increase to its share repurchase program. CEO Jeff Green noted that while results exceeded expectations, the company is moving with greater urgency to improve its growth trajectory through platform innovations like Zuma and agentic AI.
“Q3 represented meaningful progress, with results well ahead of our expectations entering the quarter, but we are still operating below the level of growth we expect from ourselves. We are moving with greater urgency across the company, strengthening how we engage with our largest customers, improving the platform through innovations such as Zuma, Audience Unlimited, agentic AI, and advancing a new approach to measurement designed to help marketers better understand what is actually driving business growth. We have more work to do, but I believe the actions we are taking are improving the underlying trajectory of the business and positioning The Trade Desk for stronger, more durable growth over the long term.”
Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.
Term
Q3 2026
“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”
Jason Coloma, Ph.D., chief executive officer of Maze
Octave Specialty Group reported third quarter 2026 financial results, highlighted by a 28% increase in total revenue to $85.3 million. The company's Insurance Distribution segment saw 35% revenue growth, while the Specialty P&C Insurance segment (Everspan) returned to profitability with $1.3 million in net income.
Term
Q3 2026
“Octave delivered a solid third quarter, with continued growth in our Insurance Distribution business and further progress at Everspan, despite a P&C market that has become more competitive as the year has progressed. While we expect market softening to continue into 2027, we believe that our operating model was built to perform through market cycles, and Octave is well positioned to deliver sustained, profitable growth toward our long-term goals.”
Claude LeBlanc, President and Chief Executive Officer
“In the third quarter, we grew our Insurance Distribution revenue 35%, including organic revenue growth of 23%. This strong organic growth, well ahead of the broader industry, is consistent with our seasonally adjusted third quarter plan and reflects the strength of our purposely diversified portfolio strategy and the strong embedded value of our scaling MGA incubator.”
Claude LeBlanc, President and Chief Executive Officer